In the News

• Feb. 5, 2012
  Avraham Pharma begins mild cognitive impairment trial
  The Ladostigil trial will include 200 patients in Israel and Europe.
• Jan. 30, 2012
  Immune Pharmaceuticals Granted US$1 Million (NIS 3.8M) by the Office of the Chief Scientist in Israel
  Funds will be used to further develop the company's lead compounds
• Jan. 24, 2012
  Avraham Pharmaceuticals reports interim Alzheimer's trial success
  Ladostigil was found to be safe and showed a positive trend in efficacy.
• Jan. 24, 2012
  BiolineRX to collaborate with Genoscience on hepatitis C
  BiolineRX has signed a worldwide, exclusive license agreement to develop and commercialize its BL-8020 drug
• Jan. 24, 2012
  Oramed Pharmaceuticals Granted Australian Patent
  The patent was granted for an important part of the company's core technology in oral delivery of proteins
• Jan. 23, 2012
  Avraham Pharmaceuticals reports interim Alzheimer's trial success
  Ladostigil was found to be safe and showed a positive trend in efficacy
• Jan. 3, 2012
  BiolineRX, Ikaria start pivotal heart attack device trial
  The BL-1040 bioabsorbable cardiac matrix aims to prevent cardiac remodeling after a heart attack.
• Jan. 1, 2012
  Brainsway jumps following Chilean agreement
  The Chilean distributor must lease at least 455 devices over 10 years
• Jan. 1, 2012
  Innovative MRI Institute Established at Shaare Zedek
  The Unit will begin accepting patients on January 15th
• Dec. 25, 2011
  Trial results boost Brainsway
  The company reported positive interim results in the safety and efficacy trial of its Deep TMS device for the treatment of multiple sclerosis
• Dec. 18, 2011
  Innovative Therapies finds innovative fund raising solution
  The company will raise $10 million via stock market shell Novo Energies, with merging into it
• Dec. 13, 2011
  BiolineRX, Compugen to jointly develop new drugs
  Compugen will provide drug candidates, which BiolineRX will develop through Phase II clinical trials
• Dec. 7, 2011
  Clal Biotech doubles stake in oncology co Biocancell
  Clal Biotech will increase its stake as part of Biocancell's NIS 11.1 million private placement
• Dec. 6, 2011
  BiolineRX jumps on positive results in neuropathic pain trial
  BL-1021 was found to be safe and effective
• Nov. 24, 2011
  Oramed mulls dual listing on TASE, upgrading to AMEX
  Oramed Pharmaceuticals is developing an insulin capsule, which is undergoing a Phase IIb clinical trial under FDA protocols.
• Nov. 22, 2011
  BioLineRx Announces Receipt of Approval in India to Commence Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia
  Trial results are expected in early 2013
• Nov. 22, 2011
  Intec Pharma reports success in sleeping pill trial
  The Zaleplon accordion pill was found to decrease sleep onset, increase sleep duration, and has no residual effects in the morning
• Nov. 22, 2011
  Eli Hurvitz 1932-2011
  "Globes" recalls the life of the man who built Teva and was "the Ben Gurion of Israel's industry."
• Nov. 17, 2011
  A quick fix for addictions and depression?
  Brainsway's revolutionary painless, non-invasive deep electromagnetic stimulation eases addiction, depression, autism and other conditions.
• Nov. 14, 2011
  Yissum, Pontifax, Clal Biotechnology Industries, TRDF and Other Investors Complete Additional Investment Round of $3 Million in Avraham Pharmaceuticals
  The capital is intended for two Phase II- clinical trials of ladostigil, a novel molecule for treatment of Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases
• Nov. 8, 2011
  Biocancell to raise $3-4m, reincorporate in Israel
  The oncology drug developer will hold a private placement from its current investors
• Nov. 1, 2011
  Moving remedies from lab to pharmacy
  Incubator takes promising new Israeli drug technologies through the first clinical testing stages and sends them on their way for finishing touches
• Oct. 23, 2011
  Brainsway reports positive results in multiple sclerosis study
  The safety and efficacy trial tested a non-invasive proprietary coil to stimulate the motor cortex for the lower limbs in patients with advanced multiple sclerosis.
• Oct. 4, 2011
  Biocancell pancreatic cancer drug wins FDA fast-track approval
  Biocancell is readying a Phase IIb clinical trial of BC-819 to test its safety and efficacy when given in conjunction with chemotherapy
• Oct. 2, 2011
  Brainsway wins Israeli approval for Deep TMS device
  The non-invasive transcranial magnetic stimulation device will be used to treat cognitive damage from major depression, bipolar depression, and schizophrenia
• Sep. 21, 2011
  Intec Pharma raises NIS 10.8m in rights issue
  The company, which develops improved versions of current drugs, received orders for 99.96% of the units offered
• Sep. 19, 2011
  "Large drug companies are stuck in a rut"
  Teva's new VC fund head Dr. Aharon Schwartz tells "Globes" about changing trends in drug development
• Sep. 15, 2011
  Path to cure for diabetes opens
  Glucose-sensing enzyme holds the key to insulin production
• Sep. 13, 2011
  FDA approves Teva's Jerusalem facility
  A new inspection of the Oral Solid Dosage facility found that it complied with current Good Manufacturing Practices
• Sep. 13, 2011
  BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain
  Results show the drug is safe and well tolerated
• Sep. 7, 2011
  BioLineRx In-Licenses BL-7050
  A Novel, Orally-Available Molecule for the Treatment of Neuropathic and Inflammatory Pain
• Aug. 11, 2011
  Chief Scientist approves NIS 5.9m Biocancell pancreatic cancer trial
  The FDA has approved a Phase IIb clinical trial (multicenter efficacy trial) of the BC-819 drug for the treatment of pancreatic cancer
• Aug. 8, 2011
  Hadasit launches Jewish-Arab biomed incubator in Galilee
  Hadasit has pledged to invest NIS 7.5 million in Ways over the next five years
• Aug. 2, 2011
  BioMarCare Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc.
  BioMarCare and Ariadne Inc. will jointly develop a diagnostic test
• Jul. 31, 2011
  Hebrew University's Yissum teams with Shaare Zedek Hospital
  Yissum CEO Yaacov Michlin: We'll be the only commercialization company in Israel that works for both a university and a hospital
• Jul. 28, 2011
  Yissum Introduces Novel Markers for Brain Cancer Survival Prognosis and a New Treatment Method for the Disease
  Findings were published in the prestigious Cancer Research journal
• Jul. 25, 2011
  BioLineRx ADRs Issues
  Begin Trading on NASDAQ
• Jul. 17, 2011
  BioMed SA strikes deal with BioJerusalem
  San Antonio mayor, BioMed SA president co-sign memorandum of intent with Jerusalem Development Authority initiative to begin building relationships to benefit biomedical sectors of both regions
• Jul. 17, 2011
  Intec Pharma jumps on positive Parkinson's results
  The company's Levodopa accordion pill was found to greatly improve current versions of the drug
• Jul. 5, 2011
  BioLineRx Announces Plans to Launch ADR Program on NASDAQ
  BioLineRx to list shares through American Depositary Receipts
• Jul. 5, 2011
  BioLineRx Announces First Subject Enrolled in Phase I Clinical Trial of BL-1021 for Neuropathic Pain
  The primary endpoints of the study are to examine the safety and tolerability of a single administration or multiple administrations of BL-1021
• Jun. 28, 2011
  BioLineRx Announces First Patient Enrolled in Phase II/III CLARITY Clinical Trial for BL-1020
  A First in Class GABA-Enhanced Antipsychotic Treatment for Schizophrenia
• Jun. 27, 2011
  BiolineRX licenses irritated bowel syndrome drug
  Yissum Technology Transfer Company of the Hebrew University previously licensed the drug to Esther Neurosciences.
• Jun. 27, 2011
  Brainsway reports success in diabetic pain and aphasia trials
  The US Veterans Administration will conduct a trial of the company's Deep TMS device to treat obesity.
• Jun. 22, 2011
  Brainsway to conduct autism clinical trial on children
  The clinical trial is part of its strategy to conduct human clinical trials to test the efficacy of the Deep TMS system
• Jun. 22, 2011
  Hebrew U device uses sonar to help the blind navigate
  The "virtual cane" incorporates several sensors that estimate the distance between the user and the object it is pointed at
• Jun. 22, 2011
  HU tech transfer co Yissum seeks to raise fund
  The fund will focus on drug development companies that have graduated from Yissum
• Jun. 21, 2011
  Pharmaceuticals and philanthropy
  Former Ivax partner Isaac Kaye donates to Hebrew University researchers and invests in Israel's life sciences
• Jun. 20, 2011
  Hadasit Bio lists on Wall Street
  Beginning today, the company's American Depository Shares are listed on the Bulletin Board under the ticker "HADSY"
• May. 26, 2011
  Cabinet to approve NIS 290m plan for Jerusalem's economy
  The funding will focus on biotech and tourism ventures
• May. 24, 2011
  Immunovative Therapies to go public through US reverse merger
  Immunovative is due to begin a Phase II/III trial of its bioengineered cell product AlloStim, a treatment for colorectal and breast cancer
• May. 22, 2011
  BiolineRX to begin clinical trial of neuropathic pain drug
  BiolineRX is developing the drug under a worldwide exclusive license Bar Ilan R&D Company and Ramot at Tel Aviv University
• May. 22, 2011
  Biocancell changes bladder cancer trial endpoint
  The company has scaled back the trial to test BC-819 on the prevention of recurrence of tumors
• May. 19, 2011
  Medinol presents positive results on new cobalt chromium stent
  Johnson & Johnson will market the stent which has fast-track FDA status designed for breakthrough technologies
• May. 17, 2011
  BiolineRX launches targeted cancer therapy project
  BL-7030 was developed by Prof. Alexander Levitsky and Dr. Alexei Shir of the Hebrew University
• May. 12, 2011
  Morria Biopharmaceuticals set to raise NIS 20m on TASE
  The British drug development company is based on technology developed at the Hebrew University.
• May. 11, 2011
  BiolineRX and Cypress cancel schizophrenia drug agreement
  Cypress Bioscience bought the rights to BL-1020 for further development of the drug, which was due to begin a Phase IIb clinical trial.
• May. 4, 2011
  Mori Arkin, Eli Hurvitz set up skin allergy co
  Omer Pharmaceuticals is based on technology developed by Collplant and CBD founder Prof. Oded Shoseyov.
• May. 2, 2011
  Israelis find key to containing cancer
  Hebrew University researchers discover how a single gene can keep malignant cells from spreading to healthy tissue.
• May. 1, 2011
  Medical device co Brainsway cuts Nasdaq offering to $20m
  The amended prospectus with the SEC states the company plans to offer 1.8 million shares at $10-12 per share at a company value of $136-164 million.
• Apr. 17, 2011
  Sanofi-Aventis invests $2.1m in Hadasit Bio portfolio co Kahr
  Hadasit Bio is also investing $1 million in the company, which is developing protein-based drugs for autoimmune diseases and cancer
• Apr. 12, 2011
  Medical device co Brainsway to raise $30m on Nasdaq
  Brainsway will use 70-75% of the proceeds to bring its non-invasive device for neurological disorders to new markets and to mass produce the device
• Apr. 12, 2011
  Yissum Presents Promising Pre-Clinical Results for Oral Delivery of the Anti-Cancer Drug Docetaxel Using a Novel Nanotechnology Approach
  Findings published in the prestigious journal "Cancer Research"
• Apr. 3, 2011
  Brainsway receives EU CE Mark for Parkinson's device
  The company will market its Deep TMS device for the treatment of Parkinson's disease and as an add-on therapy for depression
• Apr. 3, 2011
  Roche to lead Israel stem cell consortium
  The consortium is based on research by Prof. Joseph Itskovitz-Eldor of the Technion and Prof. Nissim Benvenisty of the Hebrew University
• Mar. 8, 2011
  Clal Biotech to take de facto control of Biocancell
  Biocancell has asked its largest shareholder, Clal Biotech, to assume de facto control of the company at no additional investment
• Mar. 7, 2011
  Hadasit Bio-Holdings continues empowering its companies and announces progress with clinical studies aimed at early diagnosis of cancer using a simple blood test
  Hadasit has invested about 1.2 million NIS in its portfolio company BioMarCare Technologies, which has launched a clinical study in colorectal cancer patients
• Mar. 7, 2011
  Yissum and Hadasit License Regenerative Polymeric Membrane Implants to RegeneCure
  Pre-clinical trial shows excellent healing and complete bone repair 8 weeks post–osteotomy
• Mar. 6, 2011
  Oral drug co Entera reports osteoporosis success
  On the basis of the pig trial, Entera Bio is planning a Phase I human clinical trial
• Mar. 3, 2011
  Cracking crimes with a new DNA technique
  A new invention from Israeli scientists looks deeper into DNA to show with certainty whether or not a suspect was at the scene of a crime
• Mar. 1, 2011
  Brainsway boosted by successful Parkinson's trial
  The company's non-invasive transcanial magnetic stimulation was found safe and effective in significantly improving motor function of Parkinson's patients
• Feb. 27, 2011
  Bioline looks to heart attack treatment clinical trial
  Partner Ikaria is leading the trial under a development deal from 2009
• Feb. 21, 2011
  HU researcher fortifies plant genomes by ‘editing’ DNA
  MemoGene technology has already proven to be efficient in a wide variety of plants and crops
• Jan. 26, 2011
  Brainsway reports improvements in Australian autism trial
  Brainsway reports improvements in Australian autism trial
• Jan. 23, 2011
  Royalty Pharma commits to BiolineRX's schizophrenia drug
  Earlier this month, Royalty acquired Cypress Bioscience which last year signed a licensing agreement for BiolineRX's BL-1020 therapy
• Jan. 22, 2011
  Turning the biomed dream into financial reality
  Hadasit Bio Holdings
• Jan. 17, 2011
  Biotech co Chiasma raises $5m in debt
  Seven investors, whom the company did not disclose, invested in the offering.
• Jan. 10, 2011
  Gamida Cell launches blood cancer treatment trial
  Gamida Cell is developing umbilical cord blood-based NiCord independently
• Jan. 2, 2011
  Brainsway to collaborate in US cocaine addiction study
  The US National Institute for Drug Abuse will finance the study